Showing results (81-90 of 176) with videos related to
Sort By:
Pageof 18
British Journal of Cancer|November 11, 2017
Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?Jane Margetts, Laura F Ogle, Stephen L Chan, et al.Disease Markers|March 5, 2015
Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinomaAnthony W H Chan, Stephen L Chan, Frankie K F Mo, et al.Cancer|December 20, 2011
A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinomaStephen L Chan, Frankie K F Mo, Cesar S C Wong, et al.Journal of Gastroenterology and Hepatology|June 4, 2016
Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinomaAnthony W H Chan, Charing C N Chong, Frankie K F Mo, et al.Liver International : Official Journal of the International Association for the Study of the Liver|August 9, 2016
Systematic evaluation of circulating inflammatory markers for hepatocellular carcinomaStephen L Chan, Anthony W H Chan, Allen K C Chan, et al.Journal of Gastroenterology and Hepatology|March 19, 2016
Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinomaAnthony W H Chan, Charing C N Chong, Frankie K F Mo, et al.Cancer|February 26, 2024
Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion studySarwan Bishnoi, Dusan Kotasek, Morteza Aghmesheh, et al.Journal of Cellular and Molecular Medicine|August 13, 2020
Genetic variation in ABCB5 associates with risk of hepatocellular carcinomaIdy C-Y Leung, Charing C-N Chong, Tan T Cheung, et al.Clinical Lung Cancer|February 11, 2025
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib ProgressionWesley K Y Wong, Kevin K S Mok, Giselle P C Tsui, et al.Lung Cancer (Amsterdam, Netherlands)|November 4, 2025
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinibAllen C C Chen, Florence S T Mok, Wesley K Y Wong, et al.Pageof 18